VTRS
HEALTHCAREViatris Inc
AI Insight
What's Moving VTRS Today?
No stock-specific AI insight has been generated for VTRS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.30$17.40
$15.75
Fundamentals
Market Cap$17.9B
P/E Ratio—
EPS$-0.30
Dividend Yield3.12%
Dividend / Share$0.48
ROE-2.0%
Profit Margin-2.0%
Debt / Equity—
Trading
Volume8.8M
Avg Volume (10D)—
Shares Outstanding1.16B
VTRS News
45 articles- Viatris Soared 54%: Time To Be More Careful (Rating Downgrade) (NASDAQ:VTRS)Seeking Alpha·Jun 23, 2026
- VTRS vs. DHR: Which Stock Is the Better Value Option?Yahoo Finance·Jun 23, 2026
- Are Investors Undervaluing Viatris (VTRS) Right Now?Yahoo Finance·Jun 23, 2026
- 3 US Pharmaceutical Stocks With Cash Flow And Pricing RiskSimply Wall Street·Jun 20, 2026
- How Is Viatris’ Stock Performance Compared to Other Healthcare Stocks?Barchart·Jun 19, 2026
- FDA Seeks Updated Labeling for Testosterone TherapiesYahoo Finance·Jun 18, 2026
- Viatris Completes €650 Million 4.250% Senior Notes Due 2033 to Refinance 2026 DebtTradingView·Jun 18, 2026
- Viatris (NASDAQ: VTRS) issues €650M 4.25% notes to help refinance 2026 debtStock Titan·Jun 18, 2026
- 1 Cash-Producing Stock with Exciting Potential and 2 Facing HeadwindsYahoo Finance·Jun 16, 2026
- Viatris Recognized as One of the 2026 Best Workplaces™ in CanadaYahoo Finance·Jun 16, 2026
- Viatris launches €650M 4.250% senior notes due 2033 offeringTradingView·Jun 15, 2026
- Viatris (VTRS) prices €650M 4.250% senior notes maturing 2033Stock Titan·Jun 15, 2026
- Euro Bond Sale Might Change The Case For Investing In Viatris (VTRS)Simply Wall Street·Jun 15, 2026
- Viatris (VTRS) Stock And The 58% Undervaluation Debate After A Strong Year Of ReturnsYahoo Finance·Jun 14, 2026
- Viatris Euro Debt Raise Reshapes Capital Structure And Valuation StoryYahoo Finance·Jun 14, 2026
- [424B5] Viatris Inc Prospectus Supplement (Debt Securities)Stock Titan·Jun 12, 2026
- Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?Motley Fool·Jun 11, 2026
- Johnson And Johnson ASCO 2026 Data Adds Depth To JNJ Valuation StorySimply Wall Street·Jun 6, 2026
- 3 Generic Drug Stocks to Watch as New Growth Drivers EmergeYahoo Finance·Jun 5, 2026
- How Is Zoetis’ Stock Performance Compared to Other Healthcare Stocks?Barchart·Jun 3, 2026
- Salesforce : Agentforce Life Sciences Selected by Viatris as Its Global Customer Engagement Platformwww.marketscreener.com·Jun 2, 2026
- Does FDA Review of Fast-Acting Meloxicam Shift Viatris’ (VTRS) Non-Opioid Pain Strategy?Simply Wall Street·May 31, 2026
- A Look At Johnson & Johnson (JNJ) Valuation As Investor Interest Builds Around Recent Performance MetricsSimply Wall Street·May 26, 2026
- Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data CatalystMarketbeat·May 26, 2026
- Assessing Viatris (VTRS) Valuation After FDA Review Acceptance For Fast Acting Non Opioid MeloxicamYahoo Finance·May 24, 2026
- Did New Talc Verdict and MedTech Launch Just Shift Johnson & Johnson's (JNJ) Investment Narrative?Simply Wall Street·May 23, 2026
- 1 Unpopular Stock That Should Get More Attention and 2 We Find RiskyYahoo Finance·May 23, 2026
- What Viatris (VTRS)'s Fast-Acting Pain Drug Filing and Profit Uptick Means For ShareholdersSimply Wall Street·May 21, 2026
- Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings?Yahoo Finance·May 21, 2026
- Acute Myocardial Infarction Market is Expected to Hit Growth Stride at a CAGR of 13% During the Forecast Period (2026-2036) with New Therapeutic Innovations | DelveInsightYahoo Finance·May 20, 2026
- FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain TherapyYahoo Finance UK·May 19, 2026
- 1 Stock Under $50 to Target This Week and 2 We AvoidYahoo Finance·May 19, 2026
- This Income Fund Just Completely Exited Its $37 Million Stake in Algonquin Power. Why?Motley Fool·May 18, 2026
- 5 Revealing Analyst Questions From Viatris’s Q1 Earnings CallYahoo Finance·May 18, 2026
- U.S. FDA accepts Viatris new drug application for fast-acting meloxicam for the treatment of moderate-to-severe acute painmarketscreener.com·May 18, 2026
- FDA accepts Viatris application for fast-acting meloxicamInvesting.com·May 18, 2026
- Viatris Shareholders Approve Directors, Pay and AuditorTipRanks·May 15, 2026
- Viatris Hypertension Drug Doesn’t Copy J&J Patents, Court SaysBloomberg Law News·May 13, 2026
- Viatris (VTRS) Is Up 10.6% After Q1 Beat, CFO Change And Outlook Reaffirmation - What's ChangedSimply Wall Street·May 13, 2026
Price Data
Open$15.32
Previous Close$15.38
Day High$15.80
Day Low$15.22
52 Week High$17.40
52 Week Low$8.30
52-Week Range
$8.30$17.40
$15.75
Fundamentals
Market Cap$17.9B
P/E Ratio—
EPS$-0.30
Dividend Yield3.12%
Dividend / Share$0.48
ROE-2.0%
Profit Margin-2.0%
Debt / Equity—
Trading
Volume8.8M
Avg Volume (10D)—
Shares Outstanding1.16B
About Viatris Inc
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—